• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Protagonist Therapeutics Inc.

    2/21/25 4:50:33 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTGX alert in real time by email
    S-8 1 tm256812d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 21, 2025.

     

    Registration No. 333-     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PROTAGONIST THERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

    Delaware 2834 94-0505495
         
    (State or other jurisdiction of
    incorporation or organization)
    (Primary Standard Industrial
    Classification Code Number)
    (I.R.S. Employer
    Identification Number)

     

    7707 Gateway Boulevard, Suite 140

    Newark, California 94560

    (510) 474-0170

    (Address, including zip code and telephone number, of Registrant’s principal executive offices)

     

     

    Protagonist Therapeutics, Inc. 2016 Equity Incentive Plan

    Protagonist Therapeutics, Inc. 2016 Employee Stock Purchase Plan

    (Full title of the plans)

     

     

    Dinesh V. Patel, Ph.D.

    President and Chief Executive Officer

    7707 Gateway Boulevard, Suite 140

    Newark, California 94560

    (510) 474-0170

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Ryan Murr

    Gibson, Dunn & Crutcher LLP

    555 Mission Street

    Suite 3000

    San Francisco, California 94105

    415-856-0620

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
           
    Non-accelerated filer ¨ Smaller reporting company ¨
           
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Protagonist Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering (a) 2,441,405 shares of common stock, $0.00001 par value per share (the “Common Stock”), issuable to eligible persons under the Registrant’s 2016 Equity Incentive Plan, as amended (the “2016 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed on August 15, 2016 (File No. 333-213120), March 8, 2017 (File No. 333-216532), March 7, 2018 (File No. 333-223500), March 12, 2019 (File No. 333-230213), March 10, 2020 (File No. 333-237066), March 10, 2021 (File No. 333-254090), February 28, 2022 (File No. 333-263097), March 15, 2023 (File No. 333-270573), and February 27, 2024 (File No. 333-277405), and (b) 300,000 shares of Common Stock issuable to eligible persons under the Registrant’s 2016 Employee Stock Purchase Plan (the “2016 ESPP”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed on August 15, 2016 (File No. 333-213120), March 8, 2017 (File No. 333-216532), March 7, 2018 (File No. 333-223500), March 12, 2019 (File No. 333-230213), March 10, 2020 (File No. 333-237066), March 10, 2021 (File No. 333-254090), February 28, 2022 (File No. 333-263097), March 15, 2023 (File No. 333-270573), and February 27, 2024 (File No. 333-277405) (collectively, the “Prior Registration Statements”).

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2016 Plan and the 2016 ESPP are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     

     

     

    ITEM 8. EXHIBITS

     

    Exhibit
    Number
      Description
    4.1 (1)   Amended and Restated Certificate of Incorporation of Protagonist Therapeutics, Inc.
    4.2 (2)   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Protagonist Therapeutics, Inc.
    4.2 (3)   Amended and Restated Bylaws of Protagonist Therapeutics, Inc.
    4.3 (4)   Specimen stock certificate evidencing the shares of common stock.
    5.1*   Opinion of Gibson, Dunn & Crutcher LLP.
    23.1*   Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).
    23.2*   Consent of independent registered public accounting firm.
    24.1*   Power of Attorney (included on the signature page of this Form S-8).
    99.1 (5)   Protagonist Therapeutics, Inc. 2016 Equity Incentive Plan and forms of stock option grant notice, option agreement, notice of exercise, restricted stock unit grant notice and restricted stock unit agreement thereunder.
    99.2 (6)   Protagonist Therapeutics, Inc. 2016 Employee Stock Purchase Plan.
    107*   Calculation of Filing Fee Table.

     

    (1) Filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K (File No. 001-37852), filed with the Securities and Exchange Commission on August 16, 2016, and incorporated herein by reference.
    (2) Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37852), filed with the Securities and Exchange Commission on June 26, 2024, and incorporated herein by reference.
    (3) Filed as Exhibit 3.2(b) to Registrant’s Registration Statement on Form S-1 (File No. 333-212476), filed with the Securities and Exchange Commission on August 1, 2016, and incorporated herein by reference.
    (4) Filed as Exhibit 4.1 to Registrant’s Registration Statement on Form S-1 (File No. 333-212476), filed with the Securities and Exchange Commission on August 1, 2016, and incorporated herein by reference.
    (5) Filed as Exhibit 10.2 to Registrant’s Registration Statement on Form S-1 (File No. 333-212476), filed with the Securities and Exchange Commission on August 1, 2016, and incorporated herein by reference.
    (6) Filed as Exhibit 10.3 to Registrant’s Registration Statement on Form S-1 (File No. 333-212476), filed with the Securities and Exchange Commission on August 1, 2016, and incorporated herein by reference.
    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark, State of California, on this 21st day of February, 2025.

     

    PROTAGONIST THERAPEUTICS, INC.  
         
    By: /s/ Dinesh V. Patel, Ph.D.  
      Dinesh V. Patel, Ph.D.  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dinesh V. Patel, Ph.D. and Asif Ali, and each or any one of them, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date

     

    /s/ Dinesh V. Patel, Ph.D.

      President, Chief Executive Officer and Director   February 21, 2025
    Dinesh V. Patel, Ph.D.   (Principal Executive Officer)    
             
    /s/ Asif Ali   Chief Financial Officer   February 21, 2025
    Asif Ali   (Principal Financial and Accounting Officer)    
             
    /s/ Harold E. Selick, Ph.D.   Chairman of the Board of Directors   February 21, 2025
    Harold E. Selick, Ph.D.        
             
    /s/ Bryan Giraudo   Director   February 21, 2025
    Bryan Giraudo        
             
    /s/ Sarah O’Dowd   Director   February 21, 2025
    Sarah O’Dowd        
             
    /s/ William D. Waddill   Director   February 21, 2025
    William D. Waddill        
             
    /s/ Lewis T. Williams, M.D., Ph.D.   Director   February 21, 2025
    Lewis T. Williams, M.D., Ph.D.        

     

     

     

    Get the next $PTGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PTGX

    DatePrice TargetRatingAnalyst
    6/17/2025$72.00Buy
    Citigroup
    12/6/2024$47.00Neutral
    Goldman
    12/6/2024$62.00Outperform
    BMO Capital Markets
    11/5/2024$58.00Outperform
    Wedbush
    9/24/2024$65.00Buy
    TD Cowen
    9/9/2024$60.00Buy
    Truist
    10/30/2023$32.00Overweight
    CapitalOne
    5/25/2023$30.00 → $40.00Buy
    Jefferies
    More analyst ratings

    $PTGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Protagonist Therapeutics with a new price target

      Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

      6/17/25 7:50:36 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Protagonist Therapeutics with a new price target

      Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00

      12/6/24 8:23:16 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Protagonist Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00

      12/6/24 8:11:17 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    SEC Filings

    See more
    • SEC Form 144 filed by Protagonist Therapeutics Inc.

      144 - Protagonist Therapeutics, Inc (0001377121) (Subject)

      7/22/25 4:04:36 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)

      6/26/25 4:08:54 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

      SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

      6/16/25 5:30:24 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Patel Dinesh V Ph D sold $570,534 worth of shares (10,415 units at $54.78), decreasing direct ownership by 2% to 520,603 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      7/28/25 6:08:48 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Patel Dinesh V Ph D was granted 25,000 shares and sold $2,880,044 worth of shares (52,444 units at $54.92), decreasing direct ownership by 5% to 531,018 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      7/23/25 6:57:03 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Patel Dinesh V Ph D gifted 5,000 shares, decreasing direct ownership by 0.89% to 558,462 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      7/18/25 4:01:15 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Reports Granting of Inducement Awards

      NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh

      1/6/25 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/14/24 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/12/24 4:51:49 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/4/24 1:22:14 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Financials

    Live finance-specific insights

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

      Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL

      11/21/24 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

      Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

      7/31/24 9:15:00 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Set to Join S&P SmallCap 600

      NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

      6/27/24 5:44:00 PM ET
      $PTGX
      $SPGI
      $WIRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)